US FDA Eases Up On Adverse Event Reporting During COVID-19
Executive Summary
Issued as part of the new approach to releasing guidances during the pandemic, FDA said flexibility was needed for two reasons: anticipated higher levels of absenteeism among staff for both sponsors and the agency, and the necessity of prioritizing a focus on adverse events for products used to treat coronavirus.
You may also be interested in...
US FDA Legal Office’s Pandemic Response: ‘Essentially Nonstop With Some Ebb And Flow’
Former chief counsel Stacy Cline Amin's decision to expand the office's emergency response team, coupled with longstanding professional relationships, have helped the agency’s legal division navigate the public health crisis, acting chief counsel Mark Raza tells FDLI annual meeting.
Supplement Firms Should Tighten Supply Gatekeeping As FDA Suspends Inspections
Supplement manufacturers should increase vigilance over supply chains after FDA suspends routine facility inspections and certain requirements of its foreign supplier verification program. Firms should verify even their trusted supplier’s next few certificates of analysis and step-up adverse event monitoring.
FDA’s Authority Looks Safe From Judicial Interference Following Supreme Court Abortion Pill Arguments
The agency's and the pharma industry’s worst fears – that a potential ruling in the mifepristone case might usurp the FDA’s scientific authority and throw the stability of the US drug approval process into question – seem unlikely to materialize as the majority of the Supreme Court justices signal the Alliance for Hippocratic Medicine lacks standing to sue.